Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Robert J. Motzer; Paul Russo; Viktor Grünwald; Yoshihiko Tomita; Bogdan Zurawski; Omi Parikh; Sebastiano Buti; Philippe Barthélémy; Jeffrey C. Goh; Dingwei Ye; Alejo Lingua; Jean Baptiste Lattouf; Laurence Albigès; Saby George; Brian Shuch; Jeffrey Sosman; Michael Staehler; Sergio Vázquez Estévez; Burcin Simsek; Julia Spiridigliozzi; Aleksander Chudnovsky; Axel Bex

doi:10.1007/s11523-023-00987-1

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia SpiridigliozziAleksander Chudnovsky, Axel Bex

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

langue originale	Anglais
Pages (de - à)	639-641
Nombre de pages	3
journal	Targeted Oncology
Volume	18
Numéro de publication	5
Les DOIs	https://doi.org/10.1007/s11523-023-00987-1
état	Publié - 1 sept. 2023

Accès au document

10.1007/s11523-023-00987-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., Lingua, A., Lattouf, J. B., Albigès, L., George, S., Shuch, B., Sosman, J., Staehler, M., Vázquez Estévez, S., Simsek, B., ... Bex, A. (2023). Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. Targeted Oncology, 18(5), 639-641. https://doi.org/10.1007/s11523-023-00987-1

@article{fe4181a35ebd48ca906503284d6989be,

title = "Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial",

abstract = "This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).",

author = "Motzer, {Robert J.} and Paul Russo and Viktor Gr{\"u}nwald and Yoshihiko Tomita and Bogdan Zurawski and Omi Parikh and Sebastiano Buti and Philippe Barth{\'e}l{\'e}my and Goh, {Jeffrey C.} and Dingwei Ye and Alejo Lingua and Lattouf, {Jean Baptiste} and Laurence Albig{\`e}s and Saby George and Brian Shuch and Jeffrey Sosman and Michael Staehler and {V{\'a}zquez Est{\'e}vez}, Sergio and Burcin Simsek and Julia Spiridigliozzi and Aleksander Chudnovsky and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = sep,

day = "1",

doi = "10.1007/s11523-023-00987-1",

language = "English",

volume = "18",

pages = "639--641",

journal = "Targeted Oncology",

issn = "1776-2596",

number = "5",

}

Motzer, RJ, Russo, P, Grünwald, V, Tomita, Y, Zurawski, B, Parikh, O, Buti, S, Barthélémy, P, Goh, JC, Ye, D, Lingua, A, Lattouf, JB, Albigès, L, George, S, Shuch, B, Sosman, J, Staehler, M, Vázquez Estévez, S, Simsek, B, Spiridigliozzi, J, Chudnovsky, A & Bex, A 2023, 'Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial', Targeted Oncology, VOL. 18, Numéro 5, p. 639-641. https://doi.org/10.1007/s11523-023-00987-1

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. / Motzer, Robert J.; Russo, Paul; Grünwald, Viktor et al.
Dans: Targeted Oncology, Vol 18, Numéro 5, 01.09.2023, p. 639-641.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Summary of Research

T2 - Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

AU - Motzer, Robert J.

AU - Russo, Paul

AU - Grünwald, Viktor

AU - Tomita, Yoshihiko

AU - Zurawski, Bogdan

AU - Parikh, Omi

AU - Buti, Sebastiano

AU - Barthélémy, Philippe

AU - Goh, Jeffrey C.

AU - Ye, Dingwei

AU - Lingua, Alejo

AU - Lattouf, Jean Baptiste

AU - Albigès, Laurence

AU - George, Saby

AU - Shuch, Brian

AU - Sosman, Jeffrey

AU - Staehler, Michael

AU - Vázquez Estévez, Sergio

AU - Simsek, Burcin

AU - Spiridigliozzi, Julia

AU - Chudnovsky, Aleksander

AU - Bex, Axel

PY - 2023/9/1

Y1 - 2023/9/1

N2 - This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

AB - This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

UR - http://www.scopus.com/inward/record.url?scp=85169607342&partnerID=8YFLogxK

U2 - 10.1007/s11523-023-00987-1

DO - 10.1007/s11523-023-00987-1

M3 - Article

AN - SCOPUS:85169607342

SN - 1776-2596

VL - 18

SP - 639

EP - 641

JO - Targeted Oncology

JF - Targeted Oncology

IS - 5

ER -